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Implication for health policy/practice/research/medical education:
Given results of our study on assessing the serum level of vancomycin (the loading dose of 1000 mg followed by the maintenance 
dose of 500 mg) before and after hemodialysis, it is recommended to adjust and monitor the serum level of drug in old ages even 
in the cases of using low-flux dialyzer membranes.
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Introduction: Vancomycin is a wide useable antibiotic against gram-positive bacteria species 
in different clinical setting particularly in hemodialysis patients.  
Objectives: The present study aimed to assess the serum level of vancomycin before and after 
hemodialysis. 
Patients and Methods: This cross-sectional study was performed on patients who were 
hospitalized and medicated by vancomycin with the loading dose of 1000 mg followed by 
the maintenance dose of 500 mg after each dialysis session every other day. All patients 
were dialyzed with a low-flux dialyzer membrane. Half an hour before and immediately 
after dialysis, 2 mL blood sample was taken and stored at -20°C until assaying the level of 
vancomycin.
Results: The average reduction in the serum level of vancomycin was totally 17.65 ± 1.69%. 
The mean reduction in the serum level of vancomycin was significantly higher in the patients 
aged higher than 60 years, as compared to other ones. But the level of drug was independent 
to gender or body mass index. 
Conclusion: Using low-flux dialyzer membranes, the average reduction in the serum level of 
vancomycin is expected to be in the range of 12.43% to 21.56% that age was directly associated 
with the average reduction of the level of vancomycin. Therefore, adjusting and monitoring 
the serum level of drug in old ages even in the cases of using low-flux dialyzer membranes is 
recommended. 







Received: 8 June 2018 
Accepted: 19 September 2018 










Vancomycin is a wide usable antibiotic against gram-
positive bacteria species in different clinical setting 
particularly in hemodialysis patients (1). In fact, because 
of high incidence of stenting-related bacterial infections, 
following vascular accessing, vancomycin is widely 
administered in hemodialysis patients. This antibiotic 
is excreted by kidneys and thus its renal clearance as 
well as its therapeutic plasma level should be monitored 
accurately. Therefore, plasma level of this drug should be 
monitored in patients who candidate for hemodialysis 
especially in those who receive high-flux hemodialysis 
(2-7). According to the common clinical approaches, this 
drug should be administered with a loading dose of 1 g 
following dialysis or within the last hour of each session 
of dialysis, followed by administrating maintenance dose 
of the drug in the range of 0.5 g to 1.0 g after dialysis (5,7). 
To this approach, the level of vancomycin is maintained 
between 5-20 μg/mL in most of the patients. However, 
it may be leveled lower than 10 μg/mL in about 30% to 
40% may leading antibiotic treatment failure (8,9). It can 
causally occur on highly permeable dialysis membranes 
that results in the high clearance value in these patients. 
In such situations, therapeutic and non-toxic vancomycin 






levels were recommended to be obtained by giving 1000 
mg of vancomycin, intravenously, as a loading dosage 
and 500 mg during every subsequent dialysis to achieve 
optimal drug efficacy as well as appropriate drug clearance 
(10). Moreover increasing cumulative dosages of the 
drug in those patients with renal insufficiency due to the 
failure of renal clearing process in nephrotoxicity may be 
predictable, leading high drug toxicity rate (11). 
Objectives 
The present study aimed to assess the serum level of 
vancomycin before and after hemodialysis. In other 
words, we aimed to determine the therapeutic dose of the 
drug and its main determinants in patients undergoing 
hemodialysis. 
Patients and Methods 
Study patient
This cross-sectional study was conducted at dialysis ward 
in Rasoul Akram hospital, between April and December 
2015, on patients who were hospitalized and medicated by 
vancomycin with the loading dose of 1000 mg followed by 
the maintenance dose of 500 mg after each dialysis session 
every other day. 
All patients in our study aged higher than 18 years who 
suffered end-stage renal disease requiring hemodialysis 
three times a week (every session for 3.5 to 4.0 hours). 
The subjects received vancomycin therapy due to 
prophylaxis protocol or to definitive diagnosis of bacterial 
infection. Dialysis was performed for them with a filter 
of a 1.3 m2 surface area by low-flux dialyzer membrane 
(PS13 LF, Meditechsys Co, Tehran, Iran). The baseline 
characteristics including demographics, body mass index 
(BMI), underlying disorders led to end-stage renal disease 
(diabetes mellitus, hypertension, or other diseases), drug 
history, the time of receiving vancomycin, and blood 
access of dialysis (catheter or fistula) were extracted from 
hospital files and entered into the study checklists. Half 
an hour before and immediately after dialysis, 2 mL blood 
sample was taken and stored at -20°C until assaying the 
level of vancomycin. According to the protocols, the 
therapeutic range of vancomycin was considered to be 10-
20 mg/L. 
Ethical issues
This study was approved by the ethics committee of 
Iran University of Medical Sciences. Informed consent 
was obtained from all patients or their families. Human 
rights were respected in accordance with the Helsinki 
Declaration. 
Statistical analysis
Results were presented as mean ± standard deviation (SD) 
for quantitative variables and were summarized by absolute 
frequencies and percentages for categorical variables. 
Normality of data was analyzed using the Kolmogorov-
Smirnoff test. Categorical variables were compared using 
chi-square test or Fisher’s exact test when more than 20% 
of cells with expected count of less than 5 were observed. 
Quantitative variables were also compared with t test or 
Mann-Whitney U test. For the statistical analysis, the 
statistical software SPSS version 16.0 for Windows (SPSS 
Inc., Chicago, IL) was used and P values of 0.05 or less 
were considered statistically significant. 
Results
In total, 55 patients (33 men and 22 women) were assessed. 
Of those, 70.9% aged higher than 60 years and 7.2% were 
obese (BMI > 30 kg/m2). Regarding underlying disorders 
leading end-stage renal disease, 20% suffered diabetes 
mellitus type II, 38.0% were hypertensive, and 42.0% 
suffered other diseases. Overall, 78.2% suffered from 
chronic kidney disease undergoing chronic hemodialysis. 
Regarding dose of vancomycin, 9.1% received the first 
dose, 12.7% received the second dose, 65.4% received 
the third dose, and 12.7% received the fourth dose of 
vancomycin. Of 55 patients assessed in the present survey, 
16.4% had fistula and 83.6% had catheter as vascular 
access (Table 1). 
The average reduction in the serum level of vancomycin 
was totally 17.65 ± 1.69% (ranged 12.43% to 21.56%) 
µg/mL (Table 2). There was no difference in the average 
reduction in the level of vancomycin between men and 
women (17.86% versus 17.33%, P = 0.256). However it 
was significantly higher in patients older than 60 years 
compared to younger ones (17.95% versus 16.90%, P 












Diabetes mellitus 11 (20.0)
Hypertension 20 (38.0)
Others 24 (42.0)
Type of kidney injury 
Chronic  43 (78.2)
Acute 12 (21.8)
Receiving nephrotoxic drugs 6 (10.9)








Abbreviation: BMI, Body mass index.
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= 0.035). Also, no difference was revealed in the mean 
reduction of the level of drug between obese and non-
obese patients (17.76% versus 17.64%, P = 0.891) (Table 
3). Of 55 patients assessed in the study, the post-dialysis 
serum level of vancomycin maintained at the therapeutic 
range (10-20 µg/mL) in 53 patients (96.4%); thus, adjusting 
the dose of the drug was required for only in 3.6%. 
Discussion
According to the literature, the most important factor 
affecting the reduction of the level of vancomycin in 
hemodialysis patients was the type of dialysis membrane 
that the use of high-flux membranes might lead to an 
average reduction of 35% to 50% in the level of vancomycin 
(12). Thus, adjustment of drug dosage is essential to 
avoid antimicrobial treatment failure. In contrast, the 
average reduction of the level of vancomycin in low-flux 
membranes was shown to be about 17% without need to 
following an especial protocol for adjusting drug dosage 
(13). According to our survey – which is used low flux – 
the average reduction in the serum level of vancomycin 
was revealed to be 17.6% that was comparable with the 
previous reports, indicating no need to adjust the dose 
of vancomycin during dialysis with low-flux membrane. 
More important, of baseline variables, only age was 
directly associated with average reduction of the level 
of vancomycin as reducing in the level of the drug in 
the serum increases in the patients older than 60 years 
compared to the younger ones; consequently, there is a 
need for controlling titration of the drug dosages, even 
after using low-flux dialysis membranes in these patients. 
On the other hand, the reduction of the level of the drug 
was completely independent to gender or BMI. 
In total, it seems that using a vancomycin dosing 
nomogram in conditions which high-flux membranes are 
used or in old patients who were planned to use low-flux 
membranes, can significantly improve and accelerate the 
achievement of the target trough concentrations (14).
As a rule, vancomycin is not significantly dialyzable when 
hemodialysis is performed using a low flux membrane, 
while vancomycin is dialyzable when hemodialysis is 
performed using a high flux membrane (15). However, 
except for the potential effects of type of the membrane, 
other probable confounding factors should be considered. 
Based on the results of our study, older age was the 
main factor that affects the clearance of vancomycin. As 
indicated in previous studies, preexisting renal impairment 
and concomitant therapy with other nephrotoxic should 
be also considered as potential confounders that may 
affect the efficacy of drug in dialysis patients. For instance, 
as shown in the literature, the accepted incidence of 
nephrotoxicity secondary to vancomycin monotherapy is 
<5% but increases to 43% in patients receiving concomitant 
nephrotoxic medications (16). In other words, considering 
concurrently administration of nephrotoxic agents is vital 
because it may lead to increase the toxicity of vancomycin 
synergistically, thus, adjusting the dose of vancomycin in 
these conditions is potentially required. 
Conclusion 
As a total rule, for optimal level of vancomycin during 
therapy, adequate through level of this drug should be 
maintained and below this level and also unexpected 
elevated peak level especially in old age and also in 
condition with concomitant other nephrotoxic drugs 
should be avoided. Therefore, routine monitoring of 
vancomycin in all conditions that high-flux membranes 
are applied, or other nephrotoxic agents are used should 
be planned. As an important point, in those conditions 
that low-flux membranes are used, monitoring the serum 
level of this drug should be also considered in older adults. 
Limitations of the study
This study was conducted on a small proportion of 
dialysis individuals. We suggest a larger investigation on 
this aspect of renal failure patients.
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Table 2. The mean percent reduction in serum level of vancomycin 







Table 3. The average reduction in the serum level of vancomycin (µg/
mL)
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